Webcast Unlocking the Clinical and Economic Value of FibroScan®

Unlocking the Clinical and Economic Value of FibroScan®

 · US/Eastern

About This Webcast

Strategies for Optimizing Utilization and Reimbursement in Practice. In the webinar, Dr. Alkhouri discusses the ways in which FibroScan® can be integrated and optimized in practices. A combination of noninvasive tests (NITs) can provide a predictive value in identifying patients at risk for MASLD and its more advanced form, MASH. FibroScan® is an established technology and considered the gold standard NIT for aiding in the assessment of liver fibrosis, liver steatosis and portal hypertension. FibroScan® is a reimbursable, point-of-care diagnostic tool used by primary care and specialist practices as part of the diagnostic y and management algorithm for chronic liver patients.

Speakers

Naim Alkhouri, MD

Naim Alkhouri, MD

Chief Medical Officer, Chief of Transplant Hepatology, Director of the Fatty Liver Program , Arizona Liver Health

Naim Alkhouri, M.D., is the Chief Medical Officer (CMO), Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ. Prior to joining ALH, Dr. Alkhouri served as the director of the Metabolic Health Center at the Texas Liver Institute and Associate Professor of Medicine and Pediatrics at the University of Texas (UT) Health in San Antonio, TX. Dr. Alkhouri completed his Gastroenterology and Transplant Hepatology training at the renowned Cleveland Clinic, where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic at the Cleveland Clinic Digestive Disease and Surgery Institute. An author of over 200 publications, Dr. Alkhouri is considered a key opinion leader in the field of NASH therapeutics and serves as a member of the AASLD NASH Special Interest Group (NASH SIG). Dr. Alkhouri is the recipient of a number of research awards, including the American College of Gastroenterology Junior Faculty Development Award.